Study on the molecular mechanisms of rifaximin in the treatment of non‑alcoholic steatohepatitis based on the <i>Helicobacter</i>‑DCA‑Fxr‑Hnf1α signalling pathway.

ABSTRACT: Non‑alcoholic steatohepatitis (NASH), the more progressive form of non‑alcoholic fatty liver disease, has become a major cause of cirrhosis and liver cancer. The aim of the present study was to investigate the anti‑NASH effect of the nonabsorbable antibiotic rifaximin and its specific molecular mechanisms. A methionine‑choline deficient (MCD) diet was used to induce NASH formation in mice. The mice with NASH were treated with rifaximin to observe its effects on liver fat deposition, hepatocyte inflammation and liver fibrosis. Furthermore, the intestinal microbiota of mice with NASH was analysed by 16S rRNA sequencing and terminal ileal bile acid levels were assessed using liquid chromatography‑electrospray ionization‑tandem mass spectrometry analysis. Furthermore, the correlation between t

SUBMITTER: Wan YP 

PROVIDER: S-EPMC11632295 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature